[Interferon for adjuvant therapy in melanoma; although approved, not indicated]. / Interferon als adjuvante therapie bij het melanoom: wel geregistreerd, niet geïndiceerd.
Ned Tijdschr Geneeskd
; 144(45): 2160-2, 2000 Nov 04.
Article
en Nl
| MEDLINE
| ID: mdl-11086492
ABSTRACT
The Dutch melanoma group reconsidered their 1997 consensus statement on treatment of melanoma because new studies on adjuvant treatment with interferon(IFN)-alpha have been published. These have resulted in its registration for stage IIa; for stage IIb/III IFN-alpha was already registered. Overall survival should be the main endpoint of adjuvant clinical studies, especially when treatment is associated with toxicity. Since a benefit has not been unequivocally demonstrated in melanoma with Breslow thickness > 1.5 mm and/or regional lymph node metastases, there is no need to change the Dutch consensus statement. Drug registration authorities and medical professionals should cooperate more closely.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Interferón-alfa
/
Melanoma
/
Antineoplásicos
Tipo de estudio:
Guideline
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
Nl
Revista:
Ned Tijdschr Geneeskd
Año:
2000
Tipo del documento:
Article